Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China flag China · Delayed Price · Currency is CNY
37.93
-1.02 (-2.62%)
Sep 2, 2026, 3:00 PM CST

Hangzhou Biotest Biotech Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
19.7649.25169.52106.61773.63833.59
Depreciation & Amortization
24.3823.9822.6229.1723.2510.53
Other Amortization
0.260.520.110.10.080.1
Loss (Gain) From Sale of Assets
0.04-0.250.33-0-0
Asset Writedown & Restructuring Costs
1.740.04-6.3518.78-
Loss (Gain) From Sale of Investments
0.39-4.29-7.05-3.38-14.85-1.07
Provision & Write-off of Bad Debts
1.01-0.123.523.67-5.593.21
Other Operating Activities
52.1516.2711.0536.27-48.3729.38
Change in Accounts Receivable
-21.823.79-39.78-13.57107.84-51.4
Change in Inventory
-5.49-2.043.13-14.14-48.93-60.84
Change in Accounts Payable
0.478.84-43.09-20.43-98.94145.05
Change in Other Net Operating Assets
0.38.786.532.465.311.05
Operating Cash Flow
67.59106.47128.83131.38703.21908.12
Operating Cash Flow Growth
-18.75%-17.36%-1.94%-81.32%-22.56%103.58%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-140.9-129.87-245.05-56.42-178.92-200.2
Sale of Property, Plant & Equipment
2.52.740.080.18--
Investment in Securities
-79.01251.83-601.82126.76260.84-400
Other Investing Activities
4.9978.543.8414.790.23
Investing Cash Flow
-212.42131.7-838.2574.3696.71-599.97

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
---0.24-5.56
Total Debt Issued
100--0.24-5.56
Short-Term Debt Repaid
---0.15--5.29-11
Long-Term Debt Repaid
---2.45-4.17-2.8-2.46
Total Debt Repaid
-0.27--2.6-4.17-8.08-13.46
Net Debt Issued (Repaid)
99.73--2.6-3.93-8.08-7.9
Issuance of Common Stock
-3.1524.874.17-856.14
Repurchase of Common Stock
---43.18-14.76--
Common Dividends Paid
-104.67-159.88-83.65-234.67-320.01-20.91
Other Financing Activities
-108.01-1.33---4.56-14.09
Financing Cash Flow
-112.95-158.06-104.55-249.19-332.65813.24

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-42.27-12.6810.510.89104.91-14.82
Net Cash Flow
-300.0567.44-803.48-32.55572.181,107

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-73.31-23.4-116.2374.96524.29707.92
Free Cash Flow Growth
----85.70%-25.94%82.27%
Free Cash Flow Margin
-15.96%-5.22%-20.78%16.95%27.58%38.94%
Free Cash Flow Per Share
-0.55-0.16-0.790.503.515.84
Levered Free Cash Flow
-96.68-101.94-127.36-18279.64443.47
Unlevered Free Cash Flow
-96.68-101.94-127.34-17.91279.77443.89

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
--30.31-0.273.48143.6367.92
Change in Working Capital
-32.1421.06-71.28-47.41-43.7132.37